Reviva Pharmaceuticals (NASDAQ:RVPH) Upgraded at Wall Street Zen

Reviva Pharmaceuticals (NASDAQ:RVPH) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Sunday.

Other research analysts have also recently issued research reports about the stock. Maxim Group cut shares of Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, April 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a report on Tuesday, April 21st. Finally, D. Boral Capital cut shares of Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, March 5th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Reviva Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $66.67.

Reviva Pharmaceuticals Trading Down 10.0%

NASDAQ RVPH opened at $0.68 on Friday. Reviva Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $17.20. The stock has a market cap of $8.97 million, a price-to-earnings ratio of -0.17 and a beta of 0.56. The company has a 50-day moving average price of $0.69 and a two-hundred day moving average price of $4.37.

Reviva Pharmaceuticals (NASDAQ:RVPH) last posted its earnings results on Thursday, May 14th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.10). As a group, equities research analysts expect that Reviva Pharmaceuticals will post -2.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Reviva Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Armistice Capital LLC purchased a new stake in Reviva Pharmaceuticals in the 2nd quarter worth approximately $1,026,000. Millennium Management LLC lifted its position in Reviva Pharmaceuticals by 15.0% in the 3rd quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock worth $631,000 after buying an additional 223,178 shares in the last quarter. Geode Capital Management LLC lifted its position in Reviva Pharmaceuticals by 87.6% in the 4th quarter. Geode Capital Management LLC now owns 1,048,954 shares of the company’s stock worth $293,000 after buying an additional 489,711 shares in the last quarter. State Street Corp lifted its position in Reviva Pharmaceuticals by 202.4% in the 4th quarter. State Street Corp now owns 383,200 shares of the company’s stock worth $107,000 after buying an additional 256,500 shares in the last quarter. Finally, NewEdge Advisors LLC purchased a new stake in Reviva Pharmaceuticals in the 1st quarter worth approximately $58,000. Hedge funds and other institutional investors own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.